Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01122199 · ClinicalTrials.gov registry record · Phase 1
Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Shadia Jalal.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01122199 is a Phase 1 study that has completed, run by Shadia Jalal. The registered enrollment target is 27 participants.
The verdict
NCT01122199, a Phase 1 study, has completed, sponsored by Shadia Jalal.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.
Interventions
- DRUG RAD001 + AMG479
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-05-14 |
| Est. Completion | 2015-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01122199
The ClinicalTrials.gov registry entry for NCT01122199 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shadia Jalal, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 + AMG479 is the first listed.
NCT01122199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01122199 about?
NCT01122199 is a clinical study titled "Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors". The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side e...
What is the current status of trial NCT01122199?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-05-14. Estimated completion is 2015-01-19.
What interventions are being tested in trial NCT01122199?
The interventions under investigation include: RAD001 + AMG479 (DRUG).
Who is sponsoring clinical trial NCT01122199?
This trial is sponsored by Shadia Jalal, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.